OCT 16, 2019 2:52 PM PDT

Diabetes: The next-generation therapy

WRITTEN BY: Nouran Amin

A publication in Nature Communications describes a therapeutic that can avoid the side-effects of insulin in diabetic treatments particularly hypoglycemia. Presently, insulin injections is the standard and essential treatment for the survival of individuals with type 1 or type 2 diabetes.

Learn more about the role of insulin:

The study describe the identification of a protein that can act as blood sugar and avoid the complications of insulin usage. The protein is called S100A9 and can pave the way for a better therapeutic for treating insulin deficiency.

"This protein has a bad reputation because, when it binds to its sister protein S100A8, it creates a complex called calprotectin that causes the symptoms of many inflammatory or autoimmune diseases," says Giorgio Ramadori, a researcher at the Diabetes Centre of the UNIGE Faculty of Medicine and lead author. "However, by over-expressing S100A9, we can, paradoxically, reduce its harmful combination with S100A8, hence dampening calprotectin levels."

S100A9 was administered at high doses to insulin-deficient diabetic mice models. Findings showed an overall improvement of glucose management.

"In human beings, previous studies already indicated that increased S100A9 levels correlate with reduced diabetes risks; hence, these results further bolster the clinical relevance of our data. As such, we are currently working to progress to phase I human clinical trials to directly test the safety and efficacy of S100A9 in insulin deficiency," says Professor Roberto Coppari, who is currently conducting a a clinical observation study, in collaboration with the Geneva University.

On the left, a pancreatic islet of a healthy mouse (in red, cells producing insulin). On the right, a pancreatic islet of an insulin deficient mouse (cells producing insulin are virtually absent). © UNIGE

However, researchers also discovered something else—that the protein only works in the presence of a cell-surface receptor called TLR4. TLR4 is expressed on certain cells—especially fat and immune cells.

"Why? For the moment, it remains mysterious," says Roberto Coppari.. "We also want to decipher the exact role of TLR4 in order to offer a therapeutic strategy that achieves the delicate balance of optimal blood glucose, ketone and lipid control."

Source: UNIGE

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 25, 2020
Drug Discovery & Development
Hydrochloroquine Increases Risk of Death by COVID-19
MAY 25, 2020
Hydrochloroquine Increases Risk of Death by COVID-19
Researchers have found that hydroxychloroquine is not an effective treatment for COVID-19. Their study found that it lea ...
JUN 08, 2020
Cancer
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
JUN 08, 2020
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD- ...
JUN 23, 2020
Drug Discovery & Development
FDA Warns Against Toxic Hand Sanitizers
JUN 23, 2020
FDA Warns Against Toxic Hand Sanitizers
The COVID-19 pandemic has seen demand for hand sanitizers soar in recent months. As such, the Food and Drug Administrati ...
JUN 19, 2020
Drug Discovery & Development
First Treatment To Prevent Anaphylaxis
JUN 19, 2020
First Treatment To Prevent Anaphylaxis
People living with food or drug allergies are always faced with potential life-threatening anaphylactic shock. Currently ...
JUL 04, 2020
Cardiology
Discovering a New Signal Junction Controlling Pulmonary Arterial Hypertension
JUL 04, 2020
Discovering a New Signal Junction Controlling Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a progressive and fatal disease characterized by the muscularization of blood c ...
JUL 05, 2020
Drug Discovery & Development
New Drug May Reduce Inflammation from COVID-19
JUL 05, 2020
New Drug May Reduce Inflammation from COVID-19
Scientists from the University of Toronto have identified a new drug candidate that may reduce all kinds of inflammation ...
Loading Comments...